Please login to the form below
miRagen Therapeutics
This page shows the latest miRagen Therapeutics news and features for those working in and with pharma, biotech and healthcare.
Oncology bias in pharma deals
disease) to Newron Pharmaceuticals, triggered the termination of Biotie Therapeutics' acquisition of Newron. ... 370. miRagen Therapeutics/Servier. R&D and commercialisation licence (option to co-sponsor phase III).
Latest news
-
RNA interference rebirth
Initial enthusiasm for therapeutics based on RNA interference (RNAi), commonly referred to as gene silencing, faced some setbacks in 2010 after some late-stage trial failures and the withdrawal of Roche ... An emerging group of companies, notably Regulus
-
Pfizer expands RNA development deal
Santaris, which was founded in 2003, also has strategic partnerships with miRagen Therapeutics (targeting cardiovascular disease), Shire (aimed at rare genetic disorders), GlaxoSmithKline (aimed at viral diseases), and Enzon Pharmaceuticals (for
RNA interference rebirth
More from news
Approximately 0 fully matching, plus 3 partially matching documents found.
Latest Intelligence
-
Pharma deals during April 2013
respectively. As a result, companies with ADC capabilities, such as Ambrx, Mersana Therapeutics and ImmunoGen, are becoming popular partner targets for pharma companies. ... Santaris/ BMS. April also saw the announcement of yet another Santaris deal,
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Latest appointments
-
miRagen Therapeutics bolsters senior leadership team
Meanwhile, Mori (pictured below) brings over 25 years of strategic and operational experience to his new role at miRagen Therapeutics. ... I am excited to join this talented team and contribute to the success of miRagen Therapeutics as we develop our
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
Subscribe to our email news alerts
- Sanofi and Teva to collaborate on inflammatory bowel disease drug in deal worth $1.5bn
- Eli Lilly to acquire cancer specialist Point Biopharma in deal worth $1.4bn
- Regeneron and Intellia to develop additional gene editing therapies under expanded collaboration
- Novavax’s updated COVID-19 vaccine approved by FDA for emergency use
- Alzheimer’s Research UK awards Cardiff University researchers £387,000
- Actinic keratosis – a common skin condition that can lead to skin cancer
No results were found
PMHub
Porterhouse Medical Group
The Porterhouse Medical Group provides powerful, insight-driven, healthcare communication services to the pharmaceutical industry across the globe, with a focus...
Latest intelligence
- Actinic keratosis – a common skin condition that can lead to skin cancer
- PMGroup talks to Volker Koscielny, Chief Medical Officer at Almirall, about the importance of remaining vigilant about skin checks, the prevalence of actinic keratosis in the UK and the steps...
- Man vs microbe: the fight against antimicrobial resistance
- How the emerging resistance to antibiotics is being exacerbated by a lack of research and development into new antibiotics...
- Is trust the key factor in digital HCP engagement? New whitepaper from Graphite Digital
- Based on research with HCPs in the UK, USA and France, Graphite Digital’s latest whitepaper sheds light on HCP perceptions of pharma-owned digital channels, and what organisations should be prioritising...
